Avoro Capital Advisors LLC - Q1 2018 holdings

$2.09 Billion is the total value of Avoro Capital Advisors LLC's 58 reported holdings in Q1 2018. The portfolio turnover from Q4 2017 to Q1 2018 was - .

 Value Shares↓ Weighting
PBYI NewPUMA BIOTECHNOLOGY INC$56,166,000825,368
+100.0%
2.68%
ECYT NewENDOCYTE INC$51,769,0005,695,200
+100.0%
2.47%
ARMO NewARMO BIOSCIENCES INC$45,173,0001,207,500
+100.0%
2.16%
DVAX NewDYNAVAX TECHNOLOGIES CORP$32,766,0001,650,700
+100.0%
1.56%
JNCE NewJOUNCE THERAPEUTICS INC$11,693,000523,174
+100.0%
0.56%
STML NewSTEMLINE THERAPEUTICS INC$8,022,000524,321
+100.0%
0.38%
ONCS NewONCOSEC MEDICAL INC$7,534,0004,007,696
+100.0%
0.36%
KPTI NewKARYOPHARM THERAPEUTICS INC$7,524,000560,658
+100.0%
0.36%
ACAD NewACADIA PHARMACEUTICALS INC$7,125,000317,100
+100.0%
0.34%
TNDM NewTANDEM DIABETES CARE INC$3,888,000783,910
+100.0%
0.19%
DOVA NewDOVA PHARMACEUTICALS INC$3,390,000125,000
+100.0%
0.16%
SLDB NewSOLID BIOSCIENCES INC$2,063,000275,000
+100.0%
0.10%
QURE NewUNIQURE NVshares$1,592,00067,758
+100.0%
0.08%
GBT NewGLOBAL BLOOD THERAPEUTICS INCcall$1,444,000152,000
+100.0%
0.07%
XBI NewSPDR SERIES TRUST - S&P BIOTECHput$998,000750,000
+100.0%
0.05%
ACAD NewACADIA PHARMACEUTICALS INCcall$363,000500,000
+100.0%
0.02%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2018-05-15
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
AMICUS THERAPEUTICS INC36Q3 202317.9%
MIRATI THERAPEUTICS INC.35Q3 202317.2%
BIOMARIN PHARMACEUTICAL INC31Q3 20238.0%
SAREPTA THERAPUTICS INC28Q3 202314.8%
ASCENDIS PHARMA28Q3 20239.1%
ARGENX SE26Q3 20239.5%
IOVANCE BIOTHERAPEUTICS INC26Q3 20239.1%
FENNEC PHARMACEUTICALS INC25Q3 20230.4%
MADRIGAL PHARMACEUTICALS INC22Q3 20237.2%
XENON PHARMACEUTICALS INC22Q3 20233.3%

View Avoro Capital Advisors LLC's complete holdings history.

Latest significant ownerships (13-D/G)
Avoro Capital Advisors LLC Q1 2018 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Adverum Biotechnologies, Inc.Sold outFebruary 14, 202300.0%
DICE Therapeutics, Inc.February 14, 20232,525,5555.3%
IOVANCE BIOTHERAPEUTICS, INC.February 14, 20237,020,0004.4%
IVERIC bio, Inc.February 14, 20236,750,0005.0%
Kura Oncology, Inc.February 14, 20233,105,0004.5%
Aadi Bioscience, Inc.September 26, 20222,849,40211.7%
ARENA PHARMACEUTICALS INCFebruary 11, 20221,235,0002.0%
AVADEL PHARMACEUTICALS PLCFebruary 11, 20221,670,0002.9%
FENNEC PHARMACEUTICALS INC.February 11, 20221,200,0004.6%
POINT Biopharma Global Inc.Sold outFebruary 11, 202200.0%

View Avoro Capital Advisors LLC's complete significant-ownership history.

Latest filings
TypeFiled
42024-06-14
13F-HR2024-05-15
SC 13G/A2024-04-23
13F-HR2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14

View Avoro Capital Advisors LLC's complete filings history.

Compare quarters

Export Avoro Capital Advisors LLC's holdings